| Patents for A61K 45 - Medicinal preparations containing active ingredients not provided for in groups (115,020) |
|---|
| 07/30/1998 | WO1998032425A1 Pharmaceutical formulations with delayed drug release |
| 07/30/1998 | WO1998025598A3 Methods and pharmaceutical compositions for inhibiting tumour cell growth |
| 07/30/1998 | WO1998024478A3 Tumour therapy |
| 07/30/1998 | WO1998017313A3 Soluble lymphotoxin-beta receptors, anti-lymphotoxin receptor antibodies, and anti-lymphotoxin ligand antibodies as therapeutic agents for the treatment of immunological diseases |
| 07/30/1998 | DE19703131A1 Verwendung von Chinoxalin in Dreier-Kombination mit Protease-Inhibitoren und Reverse Transkriptaseinhibitoren als Arzneimittel zur Behandlung von AIDS und/oder HIV-Infektionen Use of quinoxaline in triple combination with protease inhibitors and reverse transcriptase inhibitors as drugs for the treatment of AIDS and / or HIV infection |
| 07/30/1998 | CA2456777A1 Methods for the diagnosis, prognosis and treatment of glaucoma and related disorders |
| 07/30/1998 | CA2279260A1 Human apoptosis-associated protein; encoding dna is similar to p53 response mouse gene ei124 |
| 07/30/1998 | CA2278773A1 Quinoxaline in triple combination with protease inhibitors and reverse transcriptase inhibitors as medicines for treating aids |
| 07/30/1998 | CA2278661A1 Utilisation des antagonistes des recepteurs aux cannabinoides centraux pour reguler l'appetance |
| 07/30/1998 | CA2278623A1 Novel prostate-associated kallikrein |
| 07/30/1998 | CA2278463A1 Two human homologues of galectin-5 |
| 07/30/1998 | CA2278123A1 Use of fxr, ppar.alpha. and lxr.alpha. activators to restore barrier function, promote epidermal differentiation and inhibit proliferation |
| 07/30/1998 | CA2277166A1 Kit for inhibiting the growth of cancers, comprising a chemotherapeutic agent and a benzimidazole, and optionally a potentiator |
| 07/30/1998 | CA2276691A1 Methods for diagnosing and treating body weight related disorders in animals |
| 07/30/1998 | CA2275777A1 Treatment for premenstrual dysphoric disorder |
| 07/29/1998 | EP0855443A2 cDNA clone HE8CH90 that encodes a 7-transmembrane receptor |
| 07/29/1998 | EP0855024A1 Histone deacetylase as target for antiprotozoal agents |
| 07/29/1998 | EP0854930A1 Pharmaceutical composition useful for nucleic acid transfection, and use thereof |
| 07/29/1998 | EP0854884A1 Ligand inhibitors of insulin-like growth factor binding proteins and methods of use therefor |
| 07/29/1998 | EP0854722A1 Proteins involved in targeting of peptidyl transfer center, and corresponding therapeutic agents and methods |
| 07/29/1998 | EP0854720A1 Nk-1 receptor antagonists for prevention of neurogenic inflammation in gene therapy |
| 07/29/1998 | EP0854717A1 Use of 5ht 1b? receptor antagonist for the treatment of vascular disease |
| 07/29/1998 | EP0854713A1 Compositions of melatonin and analgetic agents and methods of use thereof |
| 07/29/1998 | EP0854711A1 gamma-RAR ANTAGONIST LIGAND OR alpha-RAR AGONIST LIGAND AS AN APOPTOSIS INHIBITOR |
| 07/29/1998 | EP0854710A2 USE OF A $g(g)-RAR-SPECIFIC AGONIST LIGAND TO INCREASE APOPTOSIS RATE |
| 07/28/1998 | US5786390 Enzyme inhibitors of enzyme monoamine oxidase |
| 07/28/1998 | US5786384 Agents for the treatment and protection of the skin |
| 07/28/1998 | US5786365 Use of nonpeptide bradykinin antagonists for the treatment and prevention of chronic fibrogenetic liver disorders, acute liver disorders and the complications associated therewith |
| 07/28/1998 | US5786348 Treating loss of bone mass or bone mineral content |
| 07/28/1998 | US5786344 Camptothecin drug combinations and methods with reduced side effects |
| 07/28/1998 | US5786336 Granulocyte macrophage progenitor stimulants, tripeptides |
| 07/28/1998 | US5786329 Muscular disorders |
| 07/28/1998 | US5786198 Photoactivated antiviral and antitumor compositions |
| 07/28/1998 | US5786157 DNA encoding human 5-HT1D receptors and uses thereof |
| 07/28/1998 | US5786148 Genetic engineering and expression vectors for antisense molecules |
| 07/28/1998 | US5785993 Reduction of adhesions using controlled delivery of active oxygen inhibitors |
| 07/28/1998 | CA2220851A1 Cdna clone he8ch90 that encodes a novel 7-transmembrane receptor |
| 07/28/1998 | CA2082527C Use of purine derivatives for anesthesia, analgesia and in vivo organ preservation |
| 07/24/1998 | CA2220856A1 Cloning of a novel g-protein coupled 7tm receptor |
| 07/23/1998 | WO1998032022A1 Growth factor-dependent diseases |
| 07/23/1998 | WO1998032017A2 Modulators of insulin receptor activity |
| 07/23/1998 | WO1998031801A1 I-flice, a novel inhibitor of tumor necrosis factor receptor-1 and cd-95 induced apoptosis |
| 07/23/1998 | WO1998031800A2 Human proteins |
| 07/23/1998 | WO1998031799A2 Polynucleotides and polypeptides encoding receptors |
| 07/23/1998 | WO1998031798A1 Human extracellular matrix-1 |
| 07/23/1998 | WO1998031707A2 Transgenic animals with disrupted npy y1 receptor genes |
| 07/23/1998 | WO1998031394A2 Tissue factor methods and compositions for coagulation and tumor treatment |
| 07/23/1998 | WO1998031390A1 Obesity protein formulations |
| 07/23/1998 | WO1998031381A1 Compositions to enhance the cytoprotective effects of polycyclic phenolic compounds through the synergistic interaction with anti-oxidants |
| 07/23/1998 | WO1998031375A1 Enhanced suppression of hiv-1 by the combination of cytidine nucleoside analogues and ctp synthase inhibitors |
| 07/23/1998 | WO1998031368A1 Dosage forms and method for ameliorating male erectile dysfunction |
| 07/23/1998 | WO1998031367A1 Method for treating acid lipase deficiency diseases with an mtp inhibitor and cholesterol lowering drugs |
| 07/23/1998 | WO1998031366A1 Method for treating atherosclerosis with an mpt inhibitor and cholesterol lowering drugs |
| 07/23/1998 | WO1998031359A1 Integrin antagonists |
| 07/23/1998 | WO1998031352A1 New formulation for inhalation having a poured bulk density of 0.28 to 0.38 g/ml, a process for preparing the formulation and the use thereof |
| 07/23/1998 | WO1998031344A1 Taste masking for unpalatable formulations |
| 07/23/1998 | WO1998031339A1 Skin preparation |
| 07/23/1998 | WO1998031324A2 Genetic alterations associated with cancer |
| 07/23/1998 | WO1998026050A3 Glutathionylspermidine synthetase |
| 07/23/1998 | WO1998018500A3 Improvements in or relating to diagnostic/therapeutic agents |
| 07/23/1998 | WO1998012334A3 Chimeric, humanized and single chain antibodies to alpha-2-antiplasmin |
| 07/23/1998 | WO1998012329A3 Composition and method for enhancing fibrinolysis using antibodies to alpha-2-antiplasmin |
| 07/23/1998 | CA2403927A1 Human extracellular matrix-1 |
| 07/23/1998 | CA2278349A1 I-flice, a novel inhibitor of tumor necrosis factor receptor-1 and cd-95 induced apoptosis |
| 07/23/1998 | CA2278248A1 Human proteins |
| 07/23/1998 | CA2278118A1 Polynucleotides and polypeptides encoding receptors |
| 07/23/1998 | CA2278055A1 Human extracellular matrix-1 |
| 07/23/1998 | CA2278023A1 Modulators of insulin receptor activity |
| 07/23/1998 | CA2277831A1 Taste masking for unpalatable formulations |
| 07/23/1998 | CA2277282A1 Obesity protein formulations |
| 07/23/1998 | CA2276758A1 Dosage forms and method for ameliorating male erectile dysfunction |
| 07/23/1998 | CA2276467A1 Method for treating atherosclerosis with an mpt inhibitor and cholesterol lowering drugs |
| 07/23/1998 | CA2271237A1 Transgenic animals with disrupted npy y1 receptor genes |
| 07/22/1998 | EP0854191A2 Human cardiac/brain tolloid-like protein |
| 07/22/1998 | EP0854187A2 Novel glucose 6-phosphate dehydrogenase gene |
| 07/22/1998 | EP0853673A1 COMPOUND HAVING SEQUENCE HOMOLOGY WITH LIPOPROTEIN ASSOCIATED PHOSPHOLIPASE A2 (Lp-PLA2)/PAF ACETYL HYDROLASE |
| 07/22/1998 | EP0853483A1 Novel peptides |
| 07/22/1998 | EP0853481A1 Compositions for treating inflammation containing certain prostaglandins and a selective cyclooxygenase-2 inhibitor |
| 07/22/1998 | EP0853477A1 At1-receptor antagonists for preventing and treating postischemic renal failure and for protecting ischemic kidneys |
| 07/22/1998 | EP0853475A1 Improved therapeutic compositions comprising bactericidal/permeability-increasing (bpi) protein products |
| 07/22/1998 | EP0608322B1 Enhanced skin penetration system for improved topical delivery of drugs |
| 07/22/1998 | EP0444157B1 Collagen-polymer conjugates |
| 07/22/1998 | CN1188407A New pharmaceutical composition with anaesthetic effect |
| 07/21/1998 | US5783598 Antiretroviral naphthoquinone compounds compositions and uses thereof |
| 07/21/1998 | US5783596 Dithiocarbamates block the induced expression of the endothelial cell surface adhesion molecule vcam-1 |
| 07/21/1998 | US5783592 Formulations for lipophilic compounds |
| 07/21/1998 | US5783583 Nalmefene, withdrawal from drug dependence, side effect reduction |
| 07/21/1998 | US5783561 Anti-gram-positive bacterial methods and materials |
| 07/21/1998 | US5783556 Formulated insulin-containing composition |
| 07/21/1998 | US5783199 Anaesthetic mixtures containing enflurane or isoflurane in combination with sevoflurane or desflurane |
| 07/21/1998 | US5783184 Administering monoclonal antibodies |
| 07/16/1998 | WO1998030706A1 Compounds, compositions and methods for the endocytic presentation of immunosuppressive factors |
| 07/16/1998 | WO1998030693A2 Tumor necrosis factor receptor 5 |
| 07/16/1998 | WO1998030691A1 Human chloride channel protein (hccp) |
| 07/16/1998 | WO1998030583A1 Complexes and combinations of fetuin with therapeutic agents |
| 07/16/1998 | WO1998030566A1 Cyclic sulfone derivatives |
| 07/16/1998 | WO1998030247A1 A method and composition for cancer treatment by enzymatic conversion of soluble radioactive toxic agents |
| 07/16/1998 | WO1998030243A1 Acetylcholinesterase inhibitors in combination with muscarinic agonists for the treatment of alzheimer's disease |
| 07/16/1998 | WO1998030240A1 Treatment of lupus nephritis with anti-cd40l compounds |
| 07/16/1998 | WO1998030231A1 Use of exendins and agonists thereof for the reduction of food intake |